JSB Market Research: Nuclear Medicine Market and Radiopharmaceuticals - Global Trends & Forecast to 2017
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Nuclear</strong> <strong>Medicine</strong> <strong>Market</strong> & <strong>Radiopharmaceuticals</strong> [SPECT/PET<br />
Radioiso<strong>to</strong>pes (Technetium, F-18)], [Beta/Alpha radiation<br />
therapy (I131, Y-90)], [Applications (Cancer/Oncology,<br />
Cardiac)] & Stable Iso<strong>to</strong>pes (Deuterium, C-13) - <strong>Global</strong> <strong>Trends</strong><br />
& <strong>Forecast</strong> <strong>to</strong> <strong>2017</strong><br />
On 13 rd June 2014<br />
The report focuses on "<strong>Nuclear</strong> <strong>Medicine</strong> <strong>Market</strong> <strong>and</strong> <strong>Radiopharmaceuticals</strong> [SPECT/PET<br />
Radioiso<strong>to</strong>pes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications<br />
(Cancer/Oncology, Cardiac)] & Stable Iso<strong>to</strong>pes (Deuterium, C-13) - <strong>Global</strong> <strong>Trends</strong> & <strong>Forecast</strong> <strong>to</strong><br />
<strong>2017</strong>"<br />
The market of radiopharmaceuticals is dominated by diagnostic radioiso<strong>to</strong>pes, comprising of<br />
SPECT <strong>and</strong> PET radioiso<strong>to</strong>pes. The lions share of the SPECT market is taken up by Tc-99m,<br />
whereas the PET market is dominated by F-18FDG iso<strong>to</strong>pe. Furthermore, the PET market will<br />
witness a double digit growth during the forecast period. The therapeutic segment contributes<br />
only 10% <strong>to</strong> the global radiopharmaceuticals market <strong>and</strong> I-131 has been considered as the gold<br />
st<strong>and</strong>ard for various oncology treatments in a combined therapy. <strong>Global</strong> nuclear medicines<br />
market is majorly driven by the increasing adoption of PET <strong>and</strong> SPECT scanners, <strong>and</strong> rising<br />
awareness for radiopharmaceuticals, whereas short half life of iso<strong>to</strong>pes <strong>and</strong> stringent regulations<br />
are the fac<strong>to</strong>rs that are hindering the growth of radiopharmaceuticals worldwide.<br />
Browse Full Report @ http://www.jsbmarketresearch.com/healthcare-medical/r-<strong>Nuclear</strong>-<br />
<strong>Medicine</strong>-<strong>Market</strong>-<strong>Radiopharmaceuticals</strong>-SPECTPET-Radioiso<strong>to</strong>pes-63721<br />
Besides highly preferred iso<strong>to</strong>pes such as Tc-99m <strong>and</strong> F-18, significant growth is witnessed for<br />
Tl-201 <strong>and</strong> Rb-82 in diagnostic market <strong>and</strong> Y-90 <strong>and</strong> Lu-177 in beta therapy radioiso<strong>to</strong>pes<br />
market. Exhaustive pipeline analysis reveals that coronary heart disease, Alzheimers disease,<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
east cancer, <strong>and</strong> bone metastasis will drive the diagnostic radiopharmaceuticals market,<br />
whereas lymphoma, prostate cancer, bone metastasis, <strong>and</strong> hepa<strong>to</strong>cellular carcinoma will boost<br />
the future of therapeutic radiopharmaceuticals. Besides new applications, the potential molecules<br />
that are expected <strong>to</strong> drive the market include Alpharadin (Ra-223), Ga-68, F-18 florbetapir, <strong>and</strong><br />
F-18 choline. Though Ra-223 application is still under clinical trial, the market is highly<br />
optimistic regarding its clinical efficiency in prostate cancer, <strong>and</strong> bone metastasis.<br />
North America held the largest share in the global radiopharmaceuticals market. The U.S. market<br />
is highly supported by the Mo-99 production of NRU reac<strong>to</strong>r (Canada) <strong>and</strong> ongoing researches in<br />
different clinical institutes such as National Cancer Institute, Avid <strong>Radiopharmaceuticals</strong> <strong>and</strong> so<br />
on. Besides developed markets, the Asia-Pacific region is expected <strong>to</strong> show a remarkable growth<br />
in the coming years. China, India, Japan, South Korea, Brazil, <strong>and</strong> South Africa are expected <strong>to</strong><br />
show a high growth potential amongst the emerging geographies. These countries are influenced<br />
by the domestic production of iso<strong>to</strong>pes by reac<strong>to</strong>rs <strong>and</strong> government initiatives.<br />
Apart from upcoming iso<strong>to</strong>pes <strong>and</strong> their applications, underst<strong>and</strong>ing of the interlinked supply<br />
chain was imperative for market estimation. Value chain analysis <strong>and</strong> pipeline analysis have<br />
taken care of such business issues <strong>to</strong> come up with a consolidated market analysis, including the<br />
present <strong>and</strong> future impact of different fac<strong>to</strong>rs. Dem<strong>and</strong> <strong>and</strong> supply analysis identifies the<br />
potential risk of the interrupted supply of Mo-99 for the Tc-99m production, due <strong>to</strong> scheduled<br />
shutdown of major reac<strong>to</strong>rs <strong>and</strong> the benchmarking trend adopted by leading players <strong>to</strong> combat<br />
such operational difficulties.<br />
The radiopharmaceutical market has been analyzed from both the radiopharmaceuticals<br />
processors <strong>and</strong> genera<strong>to</strong>r manufacturers perspectives. It has been identified that shifting from<br />
HEU <strong>to</strong> LEU is the major strategy in the processors market, while strengthening the supply chain<br />
of radiopharmaceuticals is the prime concern for the genera<strong>to</strong>r manufacturers.<br />
In addition <strong>to</strong> the market size <strong>and</strong> forecast for radioiso<strong>to</strong>pes, the report also covers competitive<br />
l<strong>and</strong>scape <strong>and</strong> key developments of major players, pipeline analysis, investment opportunities,<br />
<strong>and</strong> regula<strong>to</strong>ry affairs for established players as well as new entrants.<br />
Cus<strong>to</strong>m <strong>Research</strong>/Cus<strong>to</strong>mization details<br />
RADIOPHARMACEUTICALS MARKET<br />
1. PET <strong>and</strong> SPECT procedural volume (No. of procedures) at regional level <strong>and</strong> by Iso<strong>to</strong>pe<br />
Estimation of diagnostic <strong>and</strong> therapeutic procedures in North America, Europe, Asia, <strong>and</strong> RoW<br />
for 2010, 2011, 2012, <strong>and</strong> the forecast for <strong>2017</strong><br />
Estimation of SPECT, PET, Beta emitters <strong>and</strong> Brachytherapy procedures in North America,<br />
Europe, Asia, <strong>and</strong> RoW for 2010, 2011, 2012, <strong>and</strong> forecast for <strong>2017</strong><br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Radiopharmaceutical market for South Africa & Brazil<br />
<strong>Market</strong> size estimation for South Africa <strong>and</strong> Brazil for 2010, 2011, 2012, <strong>and</strong> forecast for <strong>2017</strong><br />
Regula<strong>to</strong>ry affairs pertaining <strong>to</strong> Radiopharmaceutical market in South Africa <strong>and</strong> Brazil<br />
2. Difference between carrier added <strong>and</strong> non carrier added Lu-177 molecule<br />
Various advantages <strong>and</strong> disadvantages of carrier added <strong>and</strong> non carrier added Lu-177 molecule<br />
3. Switzerl<strong>and</strong> <strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
<strong>Market</strong> size estimation of diagnostic <strong>and</strong> therapeutic radioiso<strong>to</strong>pes in Switzerl<strong>and</strong> for 2010, 2011,<br />
2012, <strong>and</strong> forecast for <strong>2017</strong><br />
<strong>Market</strong> size estimation of SPECT <strong>and</strong> PET iso<strong>to</strong>pes for 2010, 2011, 2012, <strong>and</strong> forecast for <strong>2017</strong><br />
<strong>Market</strong> size estimation of Beta emitters <strong>and</strong> Brachytherapy iso<strong>to</strong>pes for 2010, 2011, 2012, <strong>and</strong><br />
forecast for <strong>2017</strong><br />
Regula<strong>to</strong>ry affairs pertaining <strong>to</strong> Radiopharmaceutical market in Switzerl<strong>and</strong><br />
<strong>Market</strong> share analysis of Swiss Radiopharmaceutical market<br />
Other industries we cover:<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Advertising <strong>and</strong> Media<br />
Au<strong>to</strong>motive <strong>and</strong> Parts<br />
Consumer Goods<br />
Healthcare <strong>and</strong> Medical<br />
Finance <strong>and</strong> Banking<br />
Food <strong>and</strong> Beverages<br />
Travel <strong>and</strong> Tourism<br />
Textiles <strong>and</strong> Clothing<br />
SWOT Analysis<br />
Table of Content<br />
1 Introduction (Page No. - 28)<br />
1.1 Key Take-Aways<br />
1.2 Report Description<br />
1.3 <strong>Market</strong>s Covered<br />
1.4 Stakeholders<br />
1.5 <strong>Research</strong> Methodology<br />
1.5.1 <strong>Market</strong> Size<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
1.5.2 <strong>Market</strong> Share<br />
1.5.3 Key Data Points From Secondary Sources<br />
1.5.4 Key Data Points From Primary Sources<br />
1.5.5 Assumptions<br />
2 Summary<br />
(Page No. - 35)<br />
3 <strong>Market</strong> Overview (Page No. - 40)<br />
3.1 Definition Of <strong>Radiopharmaceuticals</strong><br />
3.2 Evolution<br />
3.3 <strong>Market</strong> Segmentation<br />
3.3.1 <strong>Radiopharmaceuticals</strong><br />
3.3.2 Stable Iso<strong>to</strong>pes<br />
3.4 <strong>Market</strong> Dynamics<br />
3.4.1 Drivers<br />
3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Dem<strong>and</strong> For<br />
<strong>Radiopharmaceuticals</strong><br />
3.4.1.2 Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage<br />
3.4.1.3 Rising Awareness Of <strong>Radiopharmaceuticals</strong> To Spur Growth<br />
3.4.1.4 Ready Availability Of <strong>Radiopharmaceuticals</strong> From Cyclotrons To Goad The Growth<br />
3.4.2 Restraints<br />
3.4.2.1 Shorter Half-Life Of <strong>Radiopharmaceuticals</strong> Restricts Its Usage<br />
3.4.2.2 High Capital To Limit The Buying Of Scanners<br />
3.4.2.3 Stringent Regula<strong>to</strong>ry Guidelines And Gmp To Negatively Impact Growth<br />
3.4.2.4 Competition From Conventional Diagnostic Procedures<br />
3.4.3 Opportunities<br />
3.4.3.1 Potential Radioiso<strong>to</strong>pes In The Pipeline<br />
3.4.3.2 High Dem<strong>and</strong> In Emerging Countries<br />
3.4.3.3 Alpha Radio Immunotherapy-Based Targeted Cancer Treatment<br />
3.4.3.4 Alternative Diagnostic Radiopharmaceutical Solutions<br />
3.4.3.5 Cyclotron Based Production<br />
3.4.3.6 Neurological Applications<br />
3.4.4 Threat<br />
3.4.4.1 Shutdown Of <strong>Nuclear</strong> Reac<strong>to</strong>rs To Impact Production Of Radioiso<strong>to</strong>pes<br />
3.5 Winning Imperatives<br />
3.5.1 Investments On New Radioiso<strong>to</strong>pes And Novel Applications<br />
3.5.2 Shift Towards Leu-Based Mo-99 Production<br />
3.6 Burning Issues<br />
3.6.1 High Cost Of Pet Cameras<br />
3.6.2 Shortage In Supply Of Technetium-99m<br />
3.7 <strong>Market</strong> Share Analysis<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
3.7.1 <strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
3.7.2 Enriched Stable Iso<strong>to</strong>pes <strong>Market</strong><br />
3.8 Value Chain Analysis<br />
3.8.1 Spect (Molybdenum-99/Technetium-99m)<br />
3.8.1.1 Pricing Structure In Different Phases Of The Value Chain<br />
3.8.1.2 Cost Modeling – Leu Based Tc-99m Production<br />
3.8.2 Pet (Fluorine-18)<br />
3.8.3 Stable Iso<strong>to</strong>pe (DEUTERIUM)<br />
3.9 Pipeline Analysis<br />
3.9.1 Diagnostic Radioiso<strong>to</strong>pes<br />
3.9.2 Therapeutic Radioiso<strong>to</strong>pes<br />
3.10 Dem<strong>and</strong> & Supply Analysis<br />
3.10.1 Dem<strong>and</strong> For Mo-99/Tc-99m<br />
3.10.1.1 Availability Of Spect Cameras To Stabilize Dem<strong>and</strong><br />
3.10.1.2 Stringent Regula<strong>to</strong>ry And Reimbursement Procedures For Alternative Iso<strong>to</strong>pes Prevents<br />
Shift From Tc-99<br />
3.10.1.3 Emerging <strong>Market</strong>s Will Enhance Usage Of Tc-99m<br />
3.10.1.4 Potential Growth Of Tc-99m Based Diagnostic Imaging<br />
3.10.1.5 Shift From Spect To Pet<br />
3.10.2 Current Status Of Mo-99 Supply<br />
3.11 Strategic Benchmarking<br />
3.11.1 Processors’ Shift From Heu To Leu Based Mo-99<br />
3.11.1.1 Contract Extension By Nordion With Aecl & Supply Agreement With Riar<br />
3.11.1.2 Agreement Of Covidien & Iae Pola<strong>to</strong>m With Maria Reac<strong>to</strong>r<br />
3.11.1.3 Agreement Of Ntp Radioiso<strong>to</strong>pes With Lantheus Medical Imaging<br />
3.11.2 Sustainable Supply Chain By Genera<strong>to</strong>rs<br />
3.11.2.1 Contract Extension Of Lantheus Medical Imaging Inc., With Ntp Radioiso<strong>to</strong>pes (PTY)<br />
Ltd.<br />
3.11.2.2 Extension Of Contract & Acquisition By Iba Group<br />
3.11.2.3 Acquisition Of Cns Therapeutics, Inc., By Covidien, Plc.<br />
3.11.2.4 Collaboration Of Ntp Radioiso<strong>to</strong>pes Pty Ltd. With Ans<strong>to</strong><br />
3.11.2.5 Expansion And Agreement Of Fujifilm Holdings Corporation<br />
3.12 Regula<strong>to</strong>ry Affairs<br />
3.12.1 Guidelines In The U.S.<br />
3.12.2 Guidelines In Europe<br />
3.12.3 Reimbursement<br />
3.12.4 Safety Of Personnel<br />
3.12.5 Waste Disposal<br />
3.12.6 Equipment & Facility<br />
3.12.7 Transportation Guidelines<br />
4 <strong>Global</strong> <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Value (Page No. - 96)<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
4.1 Introduction<br />
4.2 Diagnostic <strong>Market</strong><br />
4.2.1 Opportunity Matrix<br />
4.2.2 Spect <strong>Radiopharmaceuticals</strong><br />
4.2.2.1 Technetium-99m (TC-99m)<br />
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioiso<strong>to</strong>pes<br />
4.2.2.1.2 Fac<strong>to</strong>rs Affecting Technetium-99m <strong>Market</strong><br />
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules<br />
4.2.2.1.2.2 Lack Of Availability Of Technetium<br />
4.2.2.2 Thallium-201 (TL-201)<br />
4.2.2.2.1 Tl-201 Is A Potential Substitute For TC-99m<br />
4.2.2.3 Gallium-67 (GA-67)<br />
4.2.2.3.1 Fluorine-18 Might Seize Ga-67 <strong>Market</strong> Share In The Near Future<br />
4.2.2.4 Iodine (I-123)<br />
4.2.2.5 Others<br />
4.2.3 Pet <strong>Radiopharmaceuticals</strong><br />
4.2.3.1 Fluorine-18<br />
4.2.3.1.1 Fdg<br />
4.2.3.1.2 Florbetapir<br />
4.2.3.1.3 Fac<strong>to</strong>rs Affecting Fluorine-18 <strong>Market</strong><br />
4.2.3.1.3.1 Increasing Availability Of Pet Machines<br />
4.2.3.1.3.2 Rise In Pet Procedures Increases Dem<strong>and</strong> For Fdg<br />
4.2.3.1.3.3 High Generation Costs Of Fdg<br />
4.2.3.1.3.4 Need For Speedy & Efficient Transportation<br />
4.2.3.2 Rubidium-82 (RB-82)<br />
4.2.3.2.1 Bracco Re-Launched Cardiogen-82 In Feb-12<br />
4.2.3.3 Others<br />
4.2.3.3.1 Ga-68 Deemed As A Potential Pet Radioiso<strong>to</strong>pe<br />
4.3 Therapeutic <strong>Market</strong><br />
4.3.1 Opportunity Matrix<br />
4.3.2 Beta Emitters<br />
4.3.2.1 Iodine-131 (I-131)<br />
4.3.2.2 Yttrium-90 (Y-90)<br />
4.3.2.2.1 Y-90 <strong>Market</strong> Influenced By Popularity Of Nordion’s Therasphere<br />
4.3.2.3 Samarium-153 (SM-153)<br />
4.3.2.4 Rhenium-186 (RE-186)<br />
4.3.2.5 Lutetium-177 (LU-177)<br />
4.3.2.5.1 LU-177 Is A Potential Treatment Option For Neuroendocrine Cancer<br />
4.3.2.6 Others<br />
4.3.2.6.1 Re-188 And P-33 Are Notable Promising Iso<strong>to</strong>pe<br />
4.3.3 Alpha Emitters<br />
4.3.3.1 Radium-223 (RA-223) & Alpharadin<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
4.3.3.1.1 Successful Completion Of Phase Iii Trials In Men With Bone Metastases From Crpc<br />
4.3.3.1.2 First In-Class Alpha Pharmaceutical<br />
4.3.3.1.3 Alpharadin Is Advantageous Over Taxotere, Beta-Therapy And Brachytherapy<br />
4.3.3.1.4 Success Of Alpharadin<br />
4.3.3.1.5 Porter’s Five Forces Analysis<br />
4.3.3.1.6 Alpharadin <strong>Market</strong> Potential Post Launch<br />
4.3.3.1.7 Swot Analysis<br />
4.3.3.2 Actinium-225 (AC-225)<br />
4.3.3.3 Lead-212 (PB-212)/Bismuth-212 (BI-212)<br />
4.3.3.4 Astatine-211 (AT-211)<br />
4.3.3.5 Radium-224 (RA-224)<br />
4.3.3.6 Thorium-227 (TH-227)<br />
4.3.4 Brachytherapy<br />
4.3.4.1 U.S. To Show Slow Growth Due To Reimbursement Issues<br />
4.3.4.2 Cesium-131<br />
4.3.4.3 Iodine-125<br />
4.3.4.4 Palladium-103<br />
4.3.4.5 Iridium-192<br />
4.3.4.6 Others<br />
5 <strong>Global</strong> <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Procedural Volume (Page No. - 151)<br />
5.1 Introduction<br />
5.1.1 Hospital Based & Local Reac<strong>to</strong>rs Generated Iso<strong>to</strong>pes To Boost The Procedural <strong>Market</strong><br />
5.2 Diagnostic <strong>Market</strong><br />
5.2.1 Spect <strong>Radiopharmaceuticals</strong><br />
5.2.2 Pet <strong>Radiopharmaceuticals</strong><br />
5.3 Therapeutic <strong>Market</strong><br />
5.3.1 Beta Emitters<br />
5.3.2 Brachytherapy<br />
6 <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Application/Indication (Page No. - 165)<br />
6.1 Introduction<br />
6.2 Diagnostic <strong>Market</strong><br />
6.2.1 Spect<br />
6.2.1.1 Cardiology<br />
6.2.1.2 Lymphoma<br />
6.2.1.3 Thyroid<br />
6.2.1.4 Neurology<br />
6.2.1.4.1 Alzheimer’s, Dementia, And Parkinson’s Disease Drives Growth Of The Neurology<br />
Spect <strong>Market</strong><br />
6.2.1.5 Others<br />
6.2.2 Pet Application<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
6.2.2.1 Oncology<br />
6.2.2.1.1 Fdg F-18 Has Become A Gold St<strong>and</strong>ard For Oncology Diagnosis Using Pet Scan<br />
6.2.2.2 Cardiology<br />
6.2.2.3 Neurology<br />
6.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 Dopa) Are Potential Substitutes Of Fdg F-18<br />
6.2.2.4 Others<br />
6.3 Therapeutic Application<br />
6.3.1 Thyroid<br />
6.3.2 Bone Metastasis<br />
6.3.3 Lymphoma<br />
6.3.3.1 Novel Clinical Studies Goading Lymphoma Therapy <strong>Market</strong><br />
6.3.4 Endocrine Tumors<br />
6.3.5 Others<br />
7 Enriched Stable Iso<strong>to</strong>pes <strong>Market</strong> (Page No. - 189)<br />
7.1 Introduction<br />
7.2 <strong>Market</strong> Overview<br />
7.2.1 Asia Accounts For The Largest <strong>Market</strong> Share<br />
7.3 <strong>Market</strong> Dynamics<br />
7.3.1 Drivers<br />
7.3.1.1 Stable Iso<strong>to</strong>pes Are Natural In Origin & Hence Safe<br />
7.3.1.2 Proteomics & System Biology, Major Fac<strong>to</strong>rs To Boost The Growth Of Stables<br />
7.3.1.3 Medical Applications Propel Stable Iso<strong>to</strong>pes <strong>Market</strong> Growth<br />
7.3.2 Restraints<br />
7.3.2.1 Harmful Effects Of Stable Iso<strong>to</strong>pes Affect <strong>Market</strong> Growth<br />
7.3.2.2 High Cost Of Stables Iso<strong>to</strong>pe<br />
7.4 Enriched Stables <strong>Market</strong>, By Iso<strong>to</strong>pes<br />
7.4.1 Deuterium & O-18 Are Promising Iso<strong>to</strong>pes<br />
7.4.2 Carbon-13<br />
7.4.3 Deuterium<br />
7.4.4 Oxygen-18<br />
7.4.5 Nitrogen-15<br />
7.4.6 Other Stable Iso<strong>to</strong>pes<br />
7.5 Enriched Stables <strong>Market</strong>, By Applications<br />
7.5.1 Diagnostic & Therapeutic<br />
7.5.2 <strong>Research</strong><br />
7.5.3 Pharmaceuticals<br />
7.5.4 Industrial Sec<strong>to</strong>r<br />
8 Geographic Analysis (Page No. - 208)<br />
8.1 Introduction<br />
8.2 Diagnostic <strong>Market</strong><br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
8.2.1 North America<br />
8.2.1.1 Increasing Adoption Of Alternative Production Technologies To Make Up For The<br />
Shortage Of Mo-99<br />
8.2.2 Europe<br />
8.2.2.1 Spect And Pet Contributes Almost Equal In Europe<br />
8.2.2.2 Stringent Regulations Hindering <strong>Market</strong> Growth<br />
8.2.3 Asia<br />
8.2.3.1 Asia Promises The Highest Cagr In The <strong>Forecast</strong> Period<br />
8.2.4 Rest Of The World (Row)<br />
8.3 Therapy <strong>Market</strong><br />
8.3.1 North America<br />
8.3.1.1 <strong>Nuclear</strong> <strong>Medicine</strong> <strong>Research</strong> Drives The Beta Emitters <strong>Market</strong><br />
8.3.2 Europe<br />
8.3.3 Asia<br />
8.3.4 Rest Of The World (Row)<br />
8.4 Enriched Stable Iso<strong>to</strong>pes <strong>Market</strong><br />
8.4.1 Asia<br />
8.4.2 North America<br />
8.4.3 Europe<br />
8.4.4 Rest Of The World (Row)<br />
9 Competitive L<strong>and</strong>scape (Page No. - 251)<br />
9.1 Introduction<br />
9.2 Mergers & Acquisitions<br />
9.3 Agreements, Partnerships, Collaborations & Joint Ventures<br />
9.4 Products Launch<br />
9.5 Expansions<br />
9.6 Other Developments<br />
9.7 Approvals<br />
10 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*<br />
(Page No. - 268)<br />
10.1 Companies<br />
10.1.1 Bracco Imaging S.P.A.<br />
10.1.2 Cambridge Iso<strong>to</strong>pe Labora<strong>to</strong>ries, Inc.<br />
10.1.3 Cardinal Health, Inc.<br />
10.1.4 Covidien, Plc<br />
10.1.5 Eczacibasi-Monrol<br />
10.1.6 Fujifilm Holdings Corporation<br />
10.1.7 Ge Healthcare (Subsidiary Of General Electric Company)<br />
10.1.8 Iba Group<br />
10.1.9 Isotec, Inc. (Sigma-Aldrich)<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
10.1.10 Lantheus Medical Imaging, Inc.<br />
10.1.11 Nordion, Inc.<br />
10.1.12 Ntp Radioiso<strong>to</strong>pes (PTY), Ltd.<br />
10.1.13 Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)<br />
10.1.14 Taiyo Nippon Sanso Corporation<br />
10.1.15 Urenco Limited<br />
10.1.16 Rotem Industries, Ltd., Inc.<br />
10.2 Institutes<br />
10.2.1 Australian <strong>Nuclear</strong> Association And Technology Organization (Ans<strong>to</strong>)<br />
10.2.2 Board Of Radiation And Iso<strong>to</strong>pe Technology (Brit)<br />
10.2.3 Institute Of A<strong>to</strong>mic Energy Pola<strong>to</strong>m Radioiso<strong>to</strong>pe Centre<br />
10.2.4 Institute Of Iso<strong>to</strong>pes Co., Ltd.<br />
10.2.5 Institute Of Radioelement (IRE) *Details On Financials, Product & Services, Strategy, &<br />
Developments Might Not Be Captured In Case Of Unlisted Companies.<br />
List of Tables<br />
Table 1 Radiopharmaceutical Diagnostic <strong>Market</strong>, By Technology, 2010 – <strong>2017</strong> ($Million)<br />
Table 2 Cost Increase Of Tc-99m: Phases Of Supply Chain (%)<br />
Table 3 Cost Range: New & Modified Rig ($Million)<br />
Table 4 Cost Range: New & Modified Containers ($Million)<br />
Table 5 Cost Increase For Leu-Based Conversion (%)<br />
Table 6 Cost Impact: Phases Of Supply Chain ($/6-Day Curie)<br />
Table 7 Details Of <strong>Radiopharmaceuticals</strong> For Upcoming Diagnostic Applications, 2010 – <strong>2017</strong><br />
Table 8 Details Of <strong>Radiopharmaceuticals</strong> For Upcoming Therapeutic Applications, 2010 – <strong>2017</strong><br />
Table 9 Mo-99: Weekly Dem<strong>and</strong> (2011)<br />
Table 10 Mo-99: Production Per Week (2010)<br />
Table 11 Tc-99m: Processing Capacity (2011)<br />
Table 12 Mo-99: Potential Reac<strong>to</strong>rs<br />
Table 13 <strong>Global</strong> Radiopharmaceutical Diagnostic <strong>Market</strong>, By Technology, 2010 – <strong>2017</strong><br />
($Million)<br />
Table 14 <strong>Global</strong> Spect Radiopharmaceutical <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong> ($Million)<br />
Table 15 Spect Radiopharmaceutical <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 16 Indications Diagnosed By Tc-99m<br />
Table 17 Tc-99m <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 18 Tl-201 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 19 Ga-67 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 20 I-123 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 21 Other <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 22 Pet <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Table 23 <strong>Global</strong> Pet <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong> ($Million)<br />
Table 24 F-18 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 25 Rb-82 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 26 Other Pet <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 27 <strong>Global</strong> Beta Emitter <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong> ($Million)<br />
Table 28 Beta Emitter <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 29 I-131 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 30 Y-90 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 31 Sm-153 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 32 Re-186 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 33 Lu-177 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 34 Other Beta-Emitter <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong><br />
($Million)<br />
Table 35 Alpha Emitters Vs Beta Emitters<br />
Table 36 Hrpca Bone Metastasis Therapy <strong>Market</strong> & Alpharadin Addressable <strong>Market</strong>, 2015<br />
($Million)<br />
Table 37 Radioiso<strong>to</strong>pe Characteristics & Dose Delivery Over Time<br />
Table 38 <strong>Global</strong> Brachytherapy <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong> ($Million)<br />
Table 39 Brachytherapy <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 40 Cs-131 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 41 I-125 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 42 Pd-103 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 43 Ir-192 <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 44 Other Brachytherapy Iso<strong>to</strong>pes <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 45 Radiopharmaceutical Procedures <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> (Million)<br />
Table 46 <strong>Global</strong> Diagnostic Radiopharmaceutical Procedures <strong>Market</strong>, By Technology, 2010 –<br />
<strong>2017</strong> (Million)<br />
Table 47 <strong>Global</strong> Spect Radiopharmaceutical Procedures <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong><br />
(Million)<br />
Table 48 Spect Radiopharmaceutical Procedures <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> (Million)<br />
Table 49 <strong>Global</strong> Pet Radiopharmaceutical Procedures <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong> (Million)<br />
Table 50 Pet Radiopharmaceutical Procedures <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> (Million)<br />
Table 51 <strong>Global</strong> Therapeutic Radiopharmaceutical Procedures <strong>Market</strong>, By Type, 2010 – <strong>2017</strong><br />
(Million)<br />
Table 52 <strong>Global</strong> Beta Emitter Procedures <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong> (Million)<br />
Table 53 Beta Emitters Radiopharmaceutical Procedures <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong><br />
(Million)<br />
Table 54 <strong>Global</strong> Brachytherapy Procedures <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong> (Million)<br />
Table 55 Brachytherapy <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> (Million)<br />
Table 56 Spect Application <strong>Market</strong>, 2010 – <strong>2017</strong> ($Million)<br />
Table 57 Cardiology Spect <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 58 Lymphoma Spect <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Table 59 Thyroid Spect <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 60 Neurology Spect <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 61 Other Spect Applications <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 62 <strong>Global</strong> Pet Application <strong>Market</strong>, 2010 – <strong>2017</strong> ($Million)<br />
Table 63 Oncology Pet <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 64 Cardiology Pet <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 65 Neurology Pet <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 66 Other Pet Applications <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 67 <strong>Global</strong> Radiopharmaceutical <strong>Market</strong> For Therapeutic Applications,2010 – <strong>2017</strong><br />
($Million)<br />
Table 68 Radiopharmaceutical <strong>Market</strong> For Therapeutic Applications, By Geography,2010 –<br />
<strong>2017</strong> ($Million)<br />
Table 69 Therapeutic Radiopharmaceutical <strong>Market</strong> For Thyroid Application, By<br />
Geography,2010 – <strong>2017</strong> ($Million)<br />
Table 70 Therapeutic Radiopharmaceutical <strong>Market</strong> For Bone Metastasis Application, By<br />
Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 71 Therapeutic Radiopharmaceutical <strong>Market</strong> For Lymphoma Application, By Geography,<br />
2010 – <strong>2017</strong> ($Million)<br />
Table 72 Therapeutic Radiopharmaceutical <strong>Market</strong> For Endocrine Application, By Geography,<br />
2010 – <strong>2017</strong> ($Million)<br />
Table 73 Therapeutic Radiopharmaceutical <strong>Market</strong> For Other Applications, By Geography, 2010<br />
– <strong>2017</strong> ($Million)<br />
Table 74 <strong>Global</strong> Stable Iso<strong>to</strong>pe <strong>Market</strong>, 2010 – <strong>2017</strong> ($Million)<br />
Table 75 Stable Iso<strong>to</strong>pe <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 76 Carbon Stable Iso<strong>to</strong>pe <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 77 Deuterium Stable Iso<strong>to</strong>pe <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 78 Oxygen Stable Iso<strong>to</strong>pe <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 79 Nitrogen Stable Iso<strong>to</strong>pe <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 80 Other Stable Iso<strong>to</strong>pe <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 81 <strong>Global</strong> Enriched Stable Iso<strong>to</strong>pe <strong>Market</strong>, By Application, 2010 – <strong>2017</strong> ($Million)<br />
Table 82 Stable Iso<strong>to</strong>pes <strong>Market</strong> For Medical Applications, By Geography, 2010 – <strong>2017</strong><br />
($Million)<br />
Table 83 Stable Iso<strong>to</strong>pes <strong>Market</strong> For <strong>Research</strong> Applications, By Geography, 2010 – <strong>2017</strong><br />
($Million)<br />
Table 84 Stable Iso<strong>to</strong>pes <strong>Market</strong> For Pharmaceutical Applications, By Geography, 2010 – <strong>2017</strong><br />
($Million)<br />
Table 85 Stable Iso<strong>to</strong>pes <strong>Market</strong> For Industrial Applications, By Geography, 2010 – <strong>2017</strong><br />
($Million)<br />
Table 86 Diagnostic <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 87 Spect <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 88 Pet <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2010 – <strong>2017</strong> ($Million)<br />
Table 89 North America: Radiopharmaceutical Diagnostic <strong>Market</strong>, By Technology, 2010 – <strong>2017</strong><br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
($Million)<br />
Table 90 North America: Spect Radiopharmaceutical <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong><br />
($Million)<br />
Table<br />
List of Figures<br />
Figure 1 <strong>Global</strong> Radiopharmaceutical <strong>Market</strong>, By Segment, 2010 – <strong>2017</strong><br />
Figure 2 <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2012 ($Million)<br />
Figure 3 <strong>Global</strong> Stable Iso<strong>to</strong>pes <strong>Market</strong>, 2012 – <strong>2017</strong> ($Million)<br />
Figure 4 Evolution Of <strong>Radiopharmaceuticals</strong><br />
Figure 5 <strong>Radiopharmaceuticals</strong> <strong>Market</strong> Segmentation<br />
Figure 6 Enriched Stable Iso<strong>to</strong>pes <strong>Market</strong> Segmentation<br />
Figure 7 <strong>Market</strong> Dynamics<br />
Figure 8 <strong>Radiopharmaceuticals</strong>: <strong>Market</strong> Share Analysis, By Key Players, 2012<br />
Figure 9 Enriched Stable Iso<strong>to</strong>pe: <strong>Market</strong> Share Analysis, By Key Players, 2012<br />
Figure 10 Mo-99/Tc-99m: Supply Chain<br />
Figure 11 Tc-99m: Supply Chain Participants<br />
Figure 12 Tc-99m: Value Chain Analysis<br />
Figure 13 Tc-99m: Pricing Fac<strong>to</strong>rs<br />
Figure 14 Fluorine-18: Supply Chain<br />
Figure 15 Deuterium: Supply Chain<br />
Figure 16 Major Sponsors, Clinical Studies, 2010 – <strong>2017</strong><br />
Figure 17 Clinical Trials For Diagnostic & Therapeutic Applications Of Radioiso<strong>to</strong>pes, By<br />
Phase, 2010 – <strong>2017</strong><br />
Figure 18 Clinical Trials (Phase Iii & Iv) For Diagnostic Radioiso<strong>to</strong>pes, 2010 – <strong>2017</strong><br />
Figure 19 Upcoming Radiopharmaceutical Applications (Diagnosis), 2010 – <strong>2017</strong><br />
Figure 20 Clinical Trials (Phase Iii & Iv) For Therapeutic Radioiso<strong>to</strong>pes, 2010 – <strong>2017</strong><br />
Figure 21 Upcoming Radiopharmaceutical Applications (Therapy), 2010 – <strong>2017</strong><br />
Figure 22 Mo-99 Dem<strong>and</strong> (Six Days Curie) Per Week, 2012 Vs 2030<br />
Figure 23 Mo-99: Supply Vs Dem<strong>and</strong> Analysis, 2010 – 2020<br />
Figure 24 Shift Towards Leu From Heu<br />
Figure 25 Sustainable Supply Chain & Logistics<br />
Figure 26 Opportunity Matrix: <strong>Global</strong> Diagnostic <strong>Radiopharmaceuticals</strong> <strong>Market</strong> (2012)<br />
Figure 27 Spect Radioiso<strong>to</strong>pe <strong>Market</strong> Share (2012)<br />
Figure 28 Pet <strong>Radiopharmaceuticals</strong> <strong>Market</strong> Share (2012)<br />
Figure 29 Opportunity Matrix: <strong>Global</strong> Therapeutic <strong>Radiopharmaceuticals</strong> <strong>Market</strong> (2012)<br />
Figure 30 Ra-223 Decay Chain<br />
Figure 31 Porter’s Five Forces Analysis For Alpharadin<br />
Figure 32 Swot Analysis Of Alpharadin<br />
Figure 33 <strong>Global</strong> Radiopharmaceutical Procedures <strong>Market</strong>, 2012<br />
Figure 34 Diagnostic <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Indication (2012)<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Figure 35 Key Growth Strategies, 2010 – 2013<br />
Figure 36 Cambridge Iso<strong>to</strong>pe Labora<strong>to</strong>ries Inc.: Total Revenue And R&D Expenses, 2010 –<br />
2012 ($Billion)<br />
Figure 37 Cardinal Health, Inc.: Total Revenue, 2010 – 2012 ($Billion)<br />
Figure 38 Covidien, Plc: <strong>Radiopharmaceuticals</strong> Revenue, 2010 – 2012 ($Million)<br />
Figure 39 Fujifilm Holdings Corp: Total Revenue And R&D Expenditure, 2010 – 2012<br />
($Billion)<br />
Figure 40 IBA Group: Total <strong>Market</strong> Revenue, 2009 – 2011 ($Million)<br />
Figure 41 Isotec Inc.: Total Revenue And R&D Expenses, 2009 – 2011 ($Billion)<br />
Figure 42 Lantheus: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)<br />
Figure 43 Nordion, Inc.: Total <strong>Market</strong> Revenue, 2010 – 2012 ($Million)<br />
Figure 44 Taiyo Nippon Sanso, Corp.: Total Revenue And R&D Expenditure, 2010 – 2012<br />
($Billion)<br />
Figure 45 Urenco Limited: Total <strong>Market</strong> Revenue, 2009 – 2011 ($Billion)<br />
Related reports:<br />
Asthma Treatment Drugs <strong>Market</strong>s in China<br />
Pain <strong>and</strong> Fever Relief Drugs <strong>Market</strong>s in China<br />
About <strong>JSB</strong> <strong>Market</strong> <strong>Research</strong>:-<br />
<strong>JSB</strong> market research is a leading player in the market of research report distribution. It is<br />
one-s<strong>to</strong>p-shop for all information related <strong>to</strong> market research for any sec<strong>to</strong>r of the industry.<br />
Along with providing in-depth analysis though reports, <strong>JSB</strong> market research also provides<br />
regular updates of the market though newsletters. Our reports are a well-researched work of<br />
market researchers with an extensive knowledge <strong>and</strong> a good level of market experience.<br />
To know more on <strong>Nuclear</strong> <strong>Medicine</strong> <strong>Market</strong> & <strong>Radiopharmaceuticals</strong> [SPECT/PET<br />
Radioiso<strong>to</strong>pes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications<br />
(Cancer/Oncology, Cardiac)] & Stable Iso<strong>to</strong>pes (Deuterium, C-13) - <strong>Global</strong> <strong>Trends</strong> & <strong>Forecast</strong><br />
<strong>to</strong> <strong>2017</strong><br />
http://www.jsbmarketresearch.com/healthcare-medical/r-<strong>Nuclear</strong>-<strong>Medicine</strong>-<strong>Market</strong>-<br />
<strong>Radiopharmaceuticals</strong>-SPECTPET-Radioiso<strong>to</strong>pes-63721<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/